Quick Answer
TENAX THERAPEUTICS, INC. reported Operating Income of -$56.38 million for fiscal year 2025.
TENAX THERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$56.38M | -189.2% |
| 2024 | -$19.49M | -136.8% |
| 2023 | -$8.23M | -174.5% |
| 2022 | $11.05M | +133.8% |
| 2021 | -$32.73M | -431.7% |
| 2020 | $9.87M | +215.3% |
| 2019 | -$8.56M | -24.1% |
| 2018 | -$6.89M | +25.1% |
| 2017 | -$9.21M | +82.5% |
| 2016 | -$52.65M | -255.3% |
| 2015 | -$14.82M | +10.8% |
| 2014 | -$16.61M | -220.1% |
| 2013 | -$5.19M | +36.9% |
| 2012 | -$8.22M | -177.8% |
| 2011 | $10.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$16.81M | -263.8% | -42.5% |
| June 30, 2025 | -$11.79M | -221.2% | -4.0% |
| March 31, 2025 | -$11.34M | -190.0% | -145.5% |
| September 30, 2024 | -$4.62M | -318.1% | -25.8% |
| June 30, 2024 | -$3.67M | -397.0% | +6.1% |
| March 31, 2024 | -$3.91M | -153.9% | -284.6% |
| September 30, 2023 | $2.12M | -27.4% | +71.3% |
| June 30, 2023 | $1.24M | -56.8% | +180.3% |
- TENAX THERAPEUTICS, INC. showed a decrease of -189.2% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, TENAX THERAPEUTICS, INC.’s operating income has declined by 633.8% (from $10.56 million to -$56.38 million).
- The most recent figure is from TENAX THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: